From Pharmacy Drug Guide
Gilenya® is a prescription medication for relapsing forms of multiple sclerosis (MS), an autoimmune disease. Gilenya® is not a cure, however, it does help to manage the symptoms of MS. It works by controlling lymphocytes, the white blood cells thought to damage nerve fibers in patients with MS.
Gilenya® patient assistance programs can offer financial assistance to multiple sclerosis patients who are considering using this medication. Gilenya® is an expensive multiple sclerosis treatment. Since Gilenya® has a wholesale cost of about $48,000 annually, many patients will need insurance or other assistance in order to afford treatment. Assistance may be offered by Novartis, the drug's manufacturer; third-party prescription support programs, public assistance programs, or a patient's health insurance program.
|Available through||Novartis Patient Assistance Foundation|
|Additional programs||Gilenya® Support Program|
|Eligibility||Patients must be a U.S. resident, provide proof of income within guidelines, and not have private or public prescription coverage|
|Disclaimer||The information provided by PharmacyDrugGuide.com is not a substitute for professional medical advice, diagnosis, or treatment. Do not take any action based on the information on this page without consulting a physician.|
Gilenya® is a medication that was approved by the FDA in 2010 for the treatment of multiple sclerosis. This first-in-its-class drug offers an oral treatment option to treat relapsing forms of the disease. During drug testing, Gilenya® was shown to reduce the frequency of MS attacks and lower the severity of any attacks that occurred. While the exact mechanisms of the drug are not known, it is believed the drug helps reduce attacks on the central nervous system and offers a protection for the nerve fibers.
Gilenya® lowers the number of lymphocytes, a type of white blood cell, in the blood. It appears to keep more lymphocytes inside the lymph nodes, which means that fewer lymphocytes are available to attack the myelin sheath, a part of nerve fibers. Because Gilenya® does not destroy lymphocytes, stopping Gilenya® treatment will allow lymphocytes to return to normal over time.
Gilenya Patient Assistance Programs
The Novartis Patient Assistance Foundation offers a Gilenya® Support Program. Eligibility for the program requires the patient to be a resident of the United States, offer proof of income and not be covered by another public or private prescription drug plan. Patients must meet income limitation requirements for assistance.
Patients who may be eligible for Medicare benefits can call 800-942-3424 for patient assistance directly from Novartis. This toll-free line provides patient assistance on knowing if they may benefit from Medicare Part D enrollment. In some cases, Medicare beneficiaries may also be eligible to enroll in Novartis' Patient Assistance program.
About Patient Assistance Programs